A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma — StellaPhase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(20 sites)
United States
University of Arizona Cancer Center, Tucson, Arizona University of California San Diego Moores Cancer Center, La Jolla, California Cedars-Sinai Medical Center, Los Angeles, California University of Colorado Anschutz Medical Campus, Aurora, Colorado Rocky Mountain Cancer Centers, LLP, Lone Tree, Colorado Yale - New Haven Hospital, New Haven, Connecticut HealthPartners Cancer Research Center, Saint Paul, Minnesota Washington University School of Medicine, St Louis, Missouri Memorial Sloan Kettering Cancer Center, New York, New York University Hospitals Cleveland Medical Center, Cleveland, Ohio Cleveland Clinic, Cleveland, Ohio Providence Cancer Institute, Portland, Oregon SCRI Oncology Partners, Nashville, Tennessee Texas Oncology, Dallas, Texas University of Texas Southwestern Medical Center, Dallas, Texas University Medical Center & Texas Tech Health Science Center, Lubbock, Texas Virginia Cancer Specialists, Fairfax, Virginia Swedish Medical Center, Seattle, Washington Fred Hutchinson Cancer Center, Seattle, Washington University of Wisconsin - Carbone Cancer Center, Madison, Wisconsin Last updated January 2026